DRKTF yields 66.67% · PFE yields 6.13%● Live data
📍 DRKTF pulled ahead of the other in Year 1
Combined, DRKTF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DRKTF + PFE for your $10,000?
Darktrace plc, together with its subsidiaries, engages in the development and sale of cyber-threat defense technology solutions in the United Kingdom, the United States, Europe, and internationally. Its products include Darktrace PREVENT, an attack surface management that continuously monitors attack surface for risks, high-impact vulnerabilities and external threats; and Darktrace DETECT, which analyzes thousands of metrics to reveal subtle deviations that may signal an evolving threat, including unknown techniques and novel malware, as well as installs in minutes, identifies threats, and avoids disruption. The company's products also include Darktrace RESPOND that works autonomously to disarm attacks whenever they occur and reacts to threats in seconds, as well as works 24/7 as it frees up security teams and resources; and Darktrace HEAL, which enables organizations to restore assets and systems affected by cyber-attacks to trusted operational states through AI assistance, as well as security teams to make quick and confident decisions to keep the business up and running. It serves various areas of public sectors, global enterprises and small-to-midsize businesses, critical infrastructure, and industrial organizations, including technology, governments, global retailers, financial and insurance, healthcare, and telecommunications. The company was founded in 2013 and is headquartered in Cambridge, the United Kingdom.
Full DRKTF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.